Enfusion

ENFN · NYSE

Price unavailable right now.

No price history for this range.

Key indicators

ENFN profitability and balance sheet ratios

EPS $0.0009 in Q4 FY24, down 81.6% on a year earlier.

EPS by quarter
PeriodEPS
Q1 FY23$0.0226
Q2 FY23$0.0049
Q3 FY23$0.0143
Q4 FY23$0.0049
Q1 FY24-$0.006
Q2 FY24$0.0142
Q3 FY24$0.011
Q4 FY24$0.0009

Where the money went

Q4 FY24, from revenue to net income

Enfusion brought in $52.9M of revenue in Q4 FY24, +13.9% on a year earlier. 0¢ of every dollar became profit.

Revenue
$52.9M
Costs, expenses and taxes
$52.8M
Net income
$0.1M
Net margin
0.2%

Income statement

Revenue and profit by reporting period

Revenue
Net income
ENFN income statement, quarterly
Line itemQ2 FY24Q3 FY24Q4 FY24
Revenue$49.5M$51.2M$52.9M
Gross profit$33.5M$34.8M$36.5M
Operating income$2.7M$3.0M$1.6M
Net income$1.8M$1.4M$0.1M
Diluted EPS$0.02$0.02$0.00

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
ENFN balance sheet, quarterly
Line itemJun 2024Sep 2024Dec 2024
Total assets$120.1M$134.9M$143.3M
Total liabilities$55.8M$65.0M$70.0M
Shareholder equity$64.3M$69.9M$73.2M
Cash and short-term investments$34.4M$48.3M$54.5M
Total debt$0.0M$0.0M$0.0M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
ENFN cash flow, quarterly
Line itemQ2 FY24Q3 FY24Q4 FY24
Operating cash flow$7.3M$16.2M$9.7M
Investing cash flow−$5.7M−$2.8M−$2.7M
Financing cash flow−$0.0M−$0.0M$0.0M
Capital expenditure−$1.0M−$1.1M−$0.9M
Free cash flow$6.3M$15.1M$8.8M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.